keyword
MENU ▼
Read by QxMD icon Read
search

ziv-aflibercept

keyword
https://www.readbyqxmd.com/read/27888621/intraperitoneal-ziv-aflibercept-effectively-manages-refractory-ascites-in-colorectal-cancer-patients
#1
Chieh-Sheng Lu, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Hao-Wei Teng
Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patients who did not respond to standard chemotherapy. Fifty or 100 mg of ziv-aflibercept in 100 mL of saline solution were infused through a pigtail catheter and retained for 24 h. When the ascites drainage volumes were subsequently monitored, 73...
November 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27847621/fusion-proteins-for-treatment-of-retinal-diseases-aflibercept-ziv-aflibercept-and-conbercept
#2
REVIEW
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27798520/clinical-and-electrophysiological-evaluation-after-intravitreal-ziv-aflibercept-for-exudative-age-related-macular-degeneration
#3
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Vinicius Ferreira Kniggendorf, Eduardo Amorim Novais, André Maia, Carsten Meyer, Sung Eun Song Watanabe, Michel Eid Farah, Eduardo Büchele Rodrigues
PURPOSE: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration. METHODS: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection...
October 27, 2016: Retina
https://www.readbyqxmd.com/read/27703326/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein-occlusion
#4
Remya Paulose, Jay Chhablani, Chintan J Dedhia, Michael W Stewart, Ahmad M Mansour
AIM: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). METHODS: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 μm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 μm...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27435924/antiangiogenic-and-antitumor-activities-of-aflibercept-a-soluble-vegf-receptor-1-and-2-in-a-mouse-model-of-hepatocellular-carcinoma
#5
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF receptor-1 and -2. Here, we analyzed the mechanisms of the antitumor effects of aflibercept in mouse hepatoma models. METHODS: In in vitro studies, we determined the effects of aflibercept on human umbilical vein cell (HUVEC) proliferation and bone marrow (BM) cell differentiation to endothelial progenitor cells (EPCs)...
July 2016: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/27347566/three-month-outcome-of-ziv-aflibercept-for-diabetic-macular-edema
#6
Ameen Marashi
PURPOSE: Is to show the 3-month efficacy and safety of treatment diabetic macular edema treated with intravitreal ziv-aflibercept as studies have shown that Ziv-aflibercept does not cause retinal pigment epithelial toxicity and to study it cost effectiveness. METHODS: Ten eyes in eight patients diagnosed with central diabetic macular edema were enrolled for three consecutive intravitreal injection of ziv-aflibercept 1.25 mg every 4 weeks, a complete exam including BCVA and CRT at baseline and 12 weeks with evaluation of ocular and systemic complications...
2016: Advances in Ophthalmology & Visual System
https://www.readbyqxmd.com/read/27190127/three-month-outcome-of-intravitreal-ziv-aflibercept-in-eyes-with-diabetic-macular-oedema
#7
Ahmad M Mansour, Chintan Dedhia, Jay Chhablani
PURPOSE: We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). METHODS: Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (1.25 mg) from March 2015 to November 2015. Monitoring of best-corrected visual acuity (BCVA), intraocular inflammation, cataract progression and retinal structure by spectral domain optical coherence tomography was carried out at baseline, 1 week, 1 month, 2 months and 3 months after 3 monthly injections...
May 17, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27078613/flattening-of-a-treatment-resistant-retinal-pigment-epithelial-detachment-after-a-single-intravitreal-injection-of-ziv-aflibercept
#8
Rohit Yogi, Michael Stewart, Jay Chhablani
PURPOSE: To report flattening of a treatment-resistant retinal pigment epithelial detachment (PED) due to neovascular age-related macular degeneration after a single intravitreal injection of ziv-aflibercept (Zaltrap). METHODS: A 67-year-old woman with a neovascular age-related macular degeneration-related PED was treated with intravitreal injections of bevacizumab and ranibizumab, and in combination with verteporfin photodynamic therapy, before receiving a single intravitreal injection of ziv-aflibercept (1...
April 13, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27057668/options-for-second-line-treatment-in-metastatic-colorectal-cancer
#9
James J Lee, Weijing Sun
Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most important factors in choosing among treatment options and sequencing regimens. In addition, the choice of first-line systemic therapy will affect the options for second-line treatment...
January 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27030277/three-month-outcome-of-ziv-aflibercept-for-exudative-age-related-macular-degeneration
#10
Ahmad M Mansour, Jay Chhablani, Rafic S Antonios, Rohit Yogi, Muhammad H Younis, Rola Dakroub, Hasan Chahine
PURPOSE: In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept. METHODS: Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept intravitreal injection (1.25 mg/0.05 mL) from March 2015 to November 2015. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and by spectral domain optical coherence tomography were carried out at baseline day 1, 1 week, 1 month, 2 months and 3 months after injections...
March 30, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27002945/reconsidering-the-benefit-of-intermittent-versus-continuous-treatment-in-the-maintenance-treatment-setting-of-metastatic-colorectal-cancer
#11
REVIEW
Y Sunakawa, T Bekaii-Saab, S Stintzing
Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease. Doublet chemotherapy regimens such as FOLFOX or FOLFIRI are the mainstay of standard first-line chemotherapy in the metastatic setting. The conventional treatment as a first-line approach is continuous application until progression or intolerable toxicities. However, only one third of patients are treated until progression mainly due to the side effects of chemotherapy...
April 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/26991646/intravitreal-injections-of-ziv-aflibercept-for-diabetic-macular-edema-a-pilot-study
#12
Gabriel Costa de Andrade, João Rafael de Oliveira Dias, André Maia, Michel Eid Farah, Carsten H Meyer, Eduardo Büchele Rodrigues
PURPOSE: Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs. In terms of public health the long-term treatment with the current available drugs is very expensive and new therapies with the same or better effect should be investigated. This study sought to evaluate the efficacy and safety of intravitreal injections of ziv-aflibercept for the treatment of diabetic macular edema...
September 2016: Retina
https://www.readbyqxmd.com/read/26895445/clinical-pharmacokinetics-and-pharmacodynamics-of-ramucirumab-in-the-treatment-of-colorectal-cancer
#13
Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Susana Roselló, Andrés Cervantes
INTRODUCTION: Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer. AREAS COVERED: This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to first-line chemotherapy including anti-angiogenics...
2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/26682842/ziv-aflibercept-a-novel-option-for-the-treatment-of-polypoidal-choroidal-vasculopathy
#14
Chetan Videkar, Aditya Kapoor, Jay Chhablani, Raja Narayanan
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema...
2015: BMJ Case Reports
https://www.readbyqxmd.com/read/26655620/short-term-safety-profile-of-intravitreal-ziv-aflibercept
#15
Jay Chhablani, Raja Narayanan, Annie Mathai, Rohit Yogi, Michael Stewart
AIM: To evaluate the safety of intravitreal ziv-aflibercept (Zaltrap) in the treatment choroidal neovascularization secondary to age-related macular degeneration. METHODS: Eligible eyes with choroidal neovascularization secondary to age-related macular degeneration each received a single intravitreal injection of ziv-aflibercept. Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injection, and International Society for Clinical Electrophysiology of Vision standard electroretinography was performed at baseline and Day 30...
June 2016: Retina
https://www.readbyqxmd.com/read/26532418/factors-influencing-treatment-duration-in-metastatic-colorectic-cancer-patients-treated-with-ziv-aflibercept-a-real-world-view
#16
C W Craver, K Belk, C M Blanchette
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26355232/evaluation-of-efficacy-and-safety-markers-in-a-phase-ii-study-of-metastatic-colorectal-cancer-treated-with-aflibercept-in-the-first-line-setting
#17
Diether Lambrechts, Bernard Thienpont, Vincent Thuillier, Xavier Sagaert, Matthieu Moisse, Gilian Peuteman, Carles Pericay, Gunnar Folprecht, John Zalcberg, Chiara Zilocchi, Emmanuelle Margherini, Marielle Chiron, Eric Van Cutsem
BACKGROUND: Aflibercept (ziv-aflibercept) is an anti-angiogenic agent recently approved in combination with FOLFIRI for the treatment of metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin. Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or adverse effects have been identified. Here we present biomarker data from the randomised phase II AFFIRM trial assessing aflibercept in combination with mFOLFOX6 first line in mCRC. METHODS: Ninety-six somatic mutations in key oncogenic drivers of mCRC and 133 common single-nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes were analysed, and 27 plasma markers measured at baseline, during and after treatment...
September 29, 2015: British Journal of Cancer
https://www.readbyqxmd.com/read/26215324/ramucirumab-another-anti-angiogenic-agent-for-metastatic-colorectal-cancer-in-second-line-setting-its-impact-on-clinical-practice
#18
Gaurav Goel, Weijing Sun
The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.
2015: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/25677668/ziv-aflibercept-in-macular-disease
#19
Ahmad M Mansour, Sara I Al-Ghadban, Muhammad H Yunis, Marwan E El-Sabban
BACKGROUND/AIMS: Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept. Our purpose is to determine if ziv-aflibercept can be used in AMD and DME without ocular toxicity, to test the stability of ziv-aflibercept, and to do a cost analysis. METHODS: Prospectively, consecutive patients with AMD or DME and poor vision underwent one intravitreal injection of 0...
August 2015: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/25669849/cutbacks-at-england-s-cancer-drugs-fund
#20
(no author information available yet)
England's Cancer Drugs Fund will reduce the number of indications it pays for by nearly 30%. Projections suggested that the cost of the fund would have more than doubled by the end of the year, and the cuts will save £80 million ($121 million) by eliminating drugs such as eribulin and ziv-aflibercept.
April 2015: Cancer Discovery
keyword
keyword
66937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"